Eagle Pharmaceuticals Company Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults.
The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer.
It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer.
Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
| Country | United States |
| Founded | 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Michael Graves |
Contact Details
Address: 50 Tice Boulevard Woodcliff Lake, New Jersey 07677 United States | |
| Phone | 201 326 5300 |
| Website | eagleus.com |
Stock Details
| Ticker Symbol | EGRX |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US2697961082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Graves | Chief Executive Officer and Chairman |
| Christopher Krawtschuk CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Daniel O'Connor | Executive Vice President, Chief Strategy Officer and Head of Corporate Development |
| Dr. Valentin R. Curt M.D. | Senior Vice President of Clinical Drug Development |
| Debra Marie Hussain | Senior Vice President and Head of Commercial |